Therapeutic BCG Vaccines Market Report 2026

The therapeutic bcg vaccines market size has grown strongly in recent years. It will grow from $59.09 billion in 2025 to $62.77 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to high tb prevalence, rising research in immunotherapy, limited vaccination coverage, government health initiatives, awareness of bcg benefits.

The therapeutic bcg vaccines market size is expected to see strong growth in the next few years. It will grow to $80.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing demand for personalized vaccines, technological advancements in vaccine delivery, rising focus on immuno-oncology applications, expansion of public health programs, growing investment in biotech innovations. Major trends in the forecast period include personalized bcg therapy development, vaccine delivery innovations, expanded research in tb immunotherapy, combination therapies with bcg, government-funded immunization programs.

The growing number of tuberculosis (TB) cases worldwide is expected to drive the expansion of the therapeutic BCG vaccine market. Tuberculosis is an infectious disease that primarily affects the lungs and can be transmitted through airborne droplets when an infected person coughs or sneezes. The BCG vaccine stimulates the immune system to fight the infection without causing TB, as the bacteria used in the vaccine are weakened. It provides protection against the most severe forms of TB, including adolescent TB meningitis, which makes it an essential tool in TB prevention. For example, in February 2024, the UK Health Security Agency reported a 10.7% increase in TB cases in England, with 4,850 cases in 2023 compared to 4,380 in 2022. This rising incidence of TB is driving the demand for therapeutic BCG vaccines.

Leading companies in the therapeutic BCG vaccine market are focusing on developing vaccines for therapeutic applications in various medical conditions, including BCG immunotherapy, to expand their market reach and address growing patient needs. BCG immunotherapy involves using the BCG vaccine as a form of treatment for certain cancers, particularly bladder cancer. For instance, in July 2023, the Serum Institute of India received government approval to export its BCG vaccine to Canada for use in treating bladder cancer through immunotherapy. The live, freeze-dried BCG vaccine is administered directly into the bladder, where it targets cancer cells while minimizing damage to other parts of the body.

In May 2024, ImmunityBio, a US-based biopharmaceutical company, partnered with the Serum Institute of India to scale up manufacturing and increase global access to immunotherapy products. The partnership aims to enhance the global supply of standard and recombinant BCG vaccines for use in ImmunityBio's ANKTIVA® therapy, further expanding the role of therapeutic BCG vaccines in cancer treatment. Serum Institute of India, a leading vaccine manufacturer, produces both standard and engineered BCG strains for global distribution.

Major companies operating in the therapeutic bcg vaccines market are Merck & Co Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., Statens Serum Institute, AJ Vaccines, Bul Bio-National Center of Infectious and Parasitic Diseases Ltd, Biomed Lublin S.A., PT Bio Farma, Torlak Institute of Virology, Bacille Bilie Calmette-Guerin Laboratory, Bharat Biotech International Ltd., Shanghai Institute of Biological Products Co. Ltd., Instituto Butantan, BioCen, Panacea Biotec Ltd., Institute Pasteur de Tunis, Korean BCG Vaccine Institute.

Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2025. The regions covered in the therapeutic bcg vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the therapeutic bcg vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the therapeutic bcg vaccines market by affecting the cost of raw materials, bioreactors, and laboratory equipment essential for vaccine production. Increased import duties have led to higher production costs, particularly impacting hospitals and clinics in regions like Asia-Pacific and Europe. While some manufacturers face delays, tariffs are encouraging local production and regional supply chain diversification, ultimately fostering innovation and cost optimization in vaccine development.

The therapeutic bcg vaccines market research report is one of a series of new reports that provides therapeutic bcg vaccines market statistics, including therapeutic bcg vaccines industry global market size, regional shares, competitors with a therapeutic bcg vaccines market share, detailed therapeutic bcg vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic bcg vaccines industry. This therapeutic bcg vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The therapeutic BCG vaccine is designed to provide protection against tuberculosis (TB). The Bacillus Calmette-Guérin (BCG) vaccine, which is a form of the therapeutic BCG vaccine, is not part of the standard NHS vaccination schedule. It is generally recommended that only one dose of the BCG vaccine be administered in a lifetime.

The main types of therapeutic BCG vaccines include therapy BCG and immune BCG. Therapy BCG refers to intravesical immunotherapy, a treatment that helps the immune system destroy cancer cells and is commonly used to treat early-stage bladder cancer. BCG vaccines are used across different demographics, including both pediatric and adult populations. These vaccines are administered in various settings, such as hospitals, clinics, and other healthcare facilities.

The therapeutic BCG vaccines market consists of sales of vectors, peptides, proteins, DNA, and dendritic cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.